Arbor Biotechnologies is an early stage life sciences company pushing the boundaries of biodiscovery. Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $288.9M
Founded date: 2016
Investors 5
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | S32 | s32.com |
| - | TCG Crosso... | tcgcrossov... |
| - | Illumina V... | illuminaVe... |
| - | Ono Ventur... | onoventure... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.03.2025 | Series C | $73.9M | - |
| 10.11.2021 | Series B | $215M | - |
Mentions in press and media 12
| Date | Title | Description |
| 18.03.2025 | Arbor sails into rocky gene editing waters with $74M for rare liver disease therapy | As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead liver-targeting gene therapy into human trials. The series C was led by Arch Venture Partners and TCGX, with new investors ... |
| 18.03.2025 | Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics | Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advanc... |
| 12.03.2024 | Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease | - |
| 10.11.2021 | Arbor Biotechnologies raises $215M to treat genetic diseases | Arbor Biotechnologies has raised a $215 million Series B co-led by Ally Bridge Group, TCG Crossover and Temasek. Based in the Boston area and founded in 2016, the life sciences company is developing precision gene-editing therapeutics to tr... |
| 09.11.2021 | Arbor Biotechnologies, Inc. announced that it has received $215 million in funding from a group of investors | On November 9, 2021, Arbor Biotechnologies, Inc. closed the transaction. The company has received $215,000,000 in the transaction led by new investors Temasek Holdings (Private) Limited, Ally Bridge Group, and TCG Crossover Management, LLC ... |
| 09.11.2021 | Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics | The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWS... |
| 09.11.2021 | Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing | - |
| 09.11.2021 | Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics | The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NE... |
| 09.11.2021 | Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics | The most extensive toolbox of proprietary genomic editors in the industry to enable development of curative, next-generation genetic medicines Co-founded by David Walt, Ph.D. and Feng Zhang, Ph.D. CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWS... |
| 24.08.2021 | Vertex Pharmaceuticals : and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies | Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies August 24, 2021 Vertex to use Arbor's CRISPR gene-editing technology to enhance efforts in developing novel cell therapies for the... |
Show more